Psoriatic arthritis | Apremilast (Otezla)… new hope for psoriatic arthritis

Psoriatic arthritis | Apremilast (Otezla)… new hope for psoriatic arthritis


What’s new for psoriatic arthritis? Find out
next… Apremilast (Otezla)… new hope for psoriatic
arthritis The American College of Rheumatology puts
out hotlines on new drugs. Here’s the one on apremilast. Apremilast is the first oral
agent approved by the FDA for the treatment of PsA. While its efficacy profile is modest
compared to biologic therapy, it has a favorable safety profile and the convenience of oral
dosing. It may be most appropriate for patients with less severe joint and skin manifestations
who may not yet require a biologic DMARD. There are also emerging data in patients with
psoriasis only suggesting apremilast is moderately efficacious for controlling skin disease.
There are no radiographic data available for apremilast. Although apremilast has not been
associated with an increase in overall adverse events, infections, or malignancies, symptoms
of depression, including suicidal thoughts/behavior, and weight loss, have been reported. Comment: Safe but not as effective as I would
like.

Leave a Reply

Your email address will not be published. Required fields are marked *